Panniculitis at the Site of Subcutaneous Interferon Beta Injections in a Patient with Multiple Sclerosis
Rym Sahnoun1,2, Syrine Ben-Hammamia1,2, Ons Charfi1,2, Ghozlane Lakhoua1,2, Talel Badri2,3 and Ahmed Zaiem1,2*
1Adverse Events Collection and Analysis Department, National Center of Pharmacovigilance, Tunisia
2University of Tunis-El-Manar, Faculty of Medicine, Tunisia
3Dermatology Department, Habib Thameur Hospital, Tunisia
*Corresponding Author: Ahmed Zaiem, Adverse Events Collection and Analysis Department, National Center of Pharmacovigilance, Medicine Faculty, Tunisia.
February 19, 2021; Published: May 06, 202
Interferon-β (INF-β) is associated with a high frequency of side effects, but severe local skin reactions are still rare. We report the case of complicated panniculitis induced by subcutaneous INF-β-1a injections in a 30-year-old woman, with a multiple sclerosis history. The patient developed, four years after the start of subcutaneous INF-β-1a treatment, painful erythematous ulcerated induration, which evolved into induration and fibrosis lesions. Through this case report, we would like to emphasize on the importance of preventive measures, to avoid such severe cutaneous adverse event, which may lead to lack of compliance and disease recrudescence.
Keywords: Panniculitis; Interferon Beta; Multiple Sclerosis
- The IFN B Multiple Sclerosis Study Group. “Interferon beta-1b is effective in relapsing-remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial”. Neurology 4 (1993): 655-661.
- Neilley LK., et al. “Side effect profile of interferon beta-1b in MS: results of an open label trial”. Neurology 2 (1996): 552-4.
- Arimone Y., et al. “Updating the French Method for the Causality Assessment of Adverse Drug Reactions”. Thérapie 2 (2013): 69-76.
- Gaines AR., et al. “Interferon beta-1b injection site reactions and necroses”. Multiple Sclerosis Journal 2 (1998): 70-73.
- Lebrun C., et al. “Cutaneous Side-effects of Immunomodulators in MS”. International MS Journal/MS Forum 3 (2011): 88-94.
- Ball NJ., et al. “Lobular panniculitis at the site of subcutaneous interferon beta injections for the treatment of multiple sclerosis can histologically mimic pancreatic panniculitis. A study of 12 cases”. Journal of Cutaneous Pathology 3 (2009): 331-337.
- Soria A., et al. “Panniculitis induced by interferon beta-1a vascular toxicity”. Annales de Dermatologie et de Vénéréologie 4 (2007): 374-377.
- Buttmann M., et al. “Subcutaneous Interferon-β injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction”. Journal of Neuroimmunology 168 (2005): 175-182.
- Buttmann M., et al. “Interferon-beta is a potent inducer of interferon regulatory factor-1/2-dependent IP-10/CXCL10 expression in primary human endothelial cells”. Journal of Vascular Research1 (2007): 51-60.
- Baars JW., et al. “Lobular panniculitis after subcutaneous administration of interleukin-2 (IL-2), and its exacerbation during intravenous therapy with IL-2”. British Journal of Cancer 66 (1992): 698-699.
- Cook SD. “Approved drugs and their problems in patient care: Routes of administration and dosing”. Journal of Neurological Sciences 259 (2007): 38-41.
- Nakamura Y., et al. “Severe local skin reactions to interferon beta-lb in multiple sclerosis-improvement by deep subcutaneous injection”. European Journal of Dermatology 18 (2008): 579-582.
- Mazzon E., et al. “Severe septal panniculitis in a multiple sclerosis patient treated with interferon-beta”. International Journal of Immunopathology and Pharmacology4 (2014): 669-674.
- Weise G., et al. “Lobular panniculitis and lipoatrophy of the thighs with interferon-ß1a for intramuscular injection in a patient with multiple sclerosis”. Journal of Clinical Neuroscience 9 (2012): 1312-1313.